Relafen (Nabumetone) is a nonsteroidal anti-inflammatory drug (NSAID) that exhibits anti-inflammatory, analgesic and antipyretic properties in pharmacologic studies. As with other nonsteroidal anti-inflammatory agents, Relafen (Nabumetone) mode of action is not known. However, the ability to inhibit prostaglandin synthesis may be involved in the anti-inflammatory effect.
Relafen (Nabumetone) is indicated for acute and chronic treatment of signs and symptoms of osteoarthritis and rheumatoid arthritis.
Relafen side effects include diarrhea (14%), dyspepsia (13%), and or abdominal pain (12%).
Osteoarthritis and Rheumatoid Arthritis: The recommended starting dose of Relafen is 1000 mg taken as a single dose with or without food. Some patients may obtain more symptomatic relief from 1500 mg to 2000 mg per day. Relafen can be given in either a single or twice-daily dose. Dosages over 2000 mg per day have not been studied. The lowest effective dose should be used for chronic treatment.